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Abstract
Neuroimaging genetics has attracted growing attention and interest, which is thought to be a 
powerful strategy to examine the influence of genetic variants (i.e., single nucleotide 
polymorphisms (SNPs)) on structures or functions of human brain. In recent studies, univariate or 
multivariate regression analysis methods are typically used to capture the effective associations 
between genetic variants and quantitative traits (QTs) such as brain imaging phenotypes. The 
identified imaging QTs, although associated with certain genetic markers, may not be all disease 
specific. A useful, but underexplored, scenario could be to discover only those QTs associated 
with both genetic markers and disease status for revealing the chain from genotype to phenotype to 
symptom. In addition, multimodal brain imaging phenotypes are extracted from different 
perspectives and imaging markers consistently showing up in multimodalities may provide more 
insights for mechanistic understanding of diseases (i.e., Alzheimer’s disease (AD)). In this work, 
we propose a general framework to exploit multi-modal brain imaging phenotypes as intermediate 
traits that bridge genetic risk factors and multi-class disease status. We applied our proposed 
method to explore the relation between the well-known AD risk SNP APOE rs429358 and three 
baseline brain imaging modalities (i.e., structural magnetic resonance imaging (MRI), 
fluorodeoxyglucose positron emission tomography (FDG-PET) and F-18 florbetapir PET scans 
amyloid imaging (AV45)) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database. The empirical results demonstrate that our proposed method not only helps improve the 
performances of imaging genetic associations, but also discovers robust and consistent regions of 
interests (ROIs) across multi-modalities to guide the disease-induced interpretation.
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Introduction
Alzheimer’s disease (AD) is the most common type of neurodegenerative disorder 
characterized by progressive impairment of memory and other cognitive functions in elderly 
people worldwide (Brookmeyer et al., 2007). Effective prevention and treatment of AD is a 
major challenge, given that no disease-modifying medicine in AD is available. To address 
this challenge, many AD studies focus on systems biology of the brain to better understand 
complex neurobiological systems, from genetic factors, protein products, cellular 
components, and to the complex interplay of brain structure, function, behavior and 
cognition (Pasinetti and Hiller-Sturmhofel, 2008).
High throughput genotyping technology, coupled with multimodal brain imaging, holds 
great promise to investigate the role of genetic variation in brain structure and function. An 
emerging research field, imaging genetics, focuses on study genetics using imaging 
measures as intermediate phenotypes, which is different from case-control studies (Glahn et 
al., 2007; Gottesman and Gould, 2003), and may yield interesting results for us to 
understand the complex biological mechanism of the disease (i.e., AD).
In prior imaging genetics research, genome-wide association studies (GWAS) have been 
performed to identify the associations between single nucleotide polymorphisms (SNPs) and 
imaging quantitative traits (QTs). To address the high dimensionality of the imaging genetics 
data, some hypothesis-driven approaches have focused on a small number of genetic 
variables and searched for their QT associations in the whole brain (Brun et al., 2009; 
Filippini et al., 2009). In contrast, some other studies have focused on a limited number of 
imaging QTs and searched for their SNP associations in the entire genome (Baranzini et al., 
2009; Potkin et al., 2009). In recent studies, taking into account the inherent structure among 
genotype or phenotype data (e.g., spatial information in images or combining the effect of 
multiple genetic variants), some researchers have developed several generalized multivariate 
linear regression analysis or least square kernel machine methods to boost the detection 
power (Ge et al., 2012; Hibar et al., 2011; Kohannim et al., 2012; Kohannim et al., 2011; 
Wang et al., 2012b). Although those methods may have potentials to help discover structured 
phenotypic imaging markers related to some candidate risk SNPs, the problem of existing 
methods in imaging genetics is that phenotypes could be related to many genetic markers on 
different pathways that are not all disease specific. A valuable scenario would be to discover 
only those QTs associated with both genetic markers and disease status to better reveal the 
biological pathways specific to the disease. Thus, it is an important research topic to 
incorporate the subjects’ diagnosis information (e.g., class labels), and to discover disease-
specific imaging genetic associations on the chain from genetic data to brain to symptom.
More recently, some diagnosis information guided methods have been proposed in the field 
of imaging genetics. The method proposed in (Vounou et al., 2012; Vounou et al., 2010) 
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employed a two-step procedure for detecting genetic factors associated with imaging 
biomarkers: 1) firstly, they pre-selected the disease relevant voxel level imaging phenotypes 
with high classification performance between AD and healthy control (HC) groups using 
penalized linear discriminant analysis; 2) secondly, they identified the SNPs associated with 
the multivariate imaging biomarkers identified from the first step. Different from general 
linear regression models, another framework employed Bayesian theory for detecting 
genetic variants associated with disease related imaging QTs (Batmanghelich et al., 2013). 
The Bayesian model performed genetic identification and imaging feature selection 
simultaneously, and could identify interesting associations along the pathway from gene to 
imaging and then to symptom.
In addition, most of existing imaging genetic studies (Batmanghelich et al., 2013; Vounou et 
al., 2012; Vounou et al., 2010; Wang et al., 2012a; Wang et al., 2012b) have focused on the 
associations between only single imaging modality (e.g., magnetic resonance imaging 
(MRI)-voxel based morphometry (VBM) or FreeSurfer measures) and SNPs. These methods 
can identify interesting patterns within a certain modality, but are limited in discovery of 
consistent regional patterns across multiple modalities.
To address the above challenges, this work aims to identify consistent brain regions whose 
multimodal imaging measures can serve as intermediate traits between genetic risk factor 
and disease status. Our goal is to design a simple and powerful model to extract disease-
relevant imaging genetic associations. Accordingly, we develop a novel diagnosis-guided 
multi-modality (DGMM) framework that can discover common regions of interests (ROIs) 
that are associated with both risk genetic factors and disease status (Hao et al., 2016). In this 
study, to evaluate the effectiveness and efficiency of our DGMM method, we perform 
extensive experiments on three modalities of phenotypes, voxel-based measures extracted 
from structural MRI, fluorodeoxyglucose positron emission tomography (FDG-PET)) scans, 
and 18-F florbetapir (AV-45) PET scans (i.e., amyloid imaging data). We examine their 
associations with apolipoprotein E (APOE) SNP rs429358 (the best known AD genetic risk 
factor, see those in the AlzGene database (www.alzgene.org)) (Filippini et al., 2009; Liu et 
al., 2015). All the data are downloaded from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) cohort. The empirical results on ADNI show that our method not only 
yields improved performances under the metrics of correlation coefficient and root mean 
squared error, but also detects a compact set of consistent and robust ROIs across three 
imaging modalities which are relevant to the genetic risk marker.
Subjects
Data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 
2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. 
The primary goal of ADNI has been to test whether serial magnetic resonance imaging 
(MRI), positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of mild 
cognitive impairment (MCI) and early Alzheimer’s disease (AD). For up-to-date 
information, see www.adni-info.org.
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In the present study, a total of 913 non-Hispanic Caucasian participants with both imaging 
and genotyping data available were studied. Table 1 lists the demographics of all these 
subjects. Diagnosis was made using the standard criteria described in the ADNI-2 
procedures manual (http://www.adniinfo.org). Briefly, HC participants had no subjective or 
informant-based complaint of memory decline and normal cognitive performance. SMC 
participants had subjective memory concerns as assessed using the Cognitive Change Index 
(CCI; total score from first 12 items >16), no informant-based complaint of memory 
impairment or decline, and normal cognitive performance on the Wechsler Logical Memory 
Delayed Recall (LM-delayed) and the Mini-Mental State Examination (MMSE) (Risacher et 
al., 2015); EMCI participants had a memory concern reported by the subject, informant, 
clinician, abnormal memory function approximately 1 standard deviation below normative 
performance adjusted for education level on the LM-delayed, an MMSE total score greater 
than 24; Besides a subjective memory concern as reported by subject, study partner or 
clinician, Clinical Dementia Rating (CDR) on LMCI subjects was 0.5 and Memory Box 
(MB) score must be at least 0.5 ; MMSE score on AD should be between 20 and 26 and 
CDR should be 0.5 or 1.0.
Risk SNP Genotype Data
Genetic risk factors can help scientists focus on relevant biological pathways and networks 
and form effective hypothesis for drug design. Given a genetic risk SNP, it is also important 
to identify its quantitative traits at brain structure and functional level to help understand the 
underlying biological mechanism.
Some researchers have identified a number of genes in addition to APOE ε4 that may 
increase a person's risk for Alzheimer’s disease (AD), including BIN1, CLU, PICALM, and 
CR1, see those in Lambert et al. (Lambert et al., 2013) and the AlzGene database 
(www.alzgene.org). APOE ε4 is called a risk-factor gene because it increases a person's risk 
of developing the disease. To our knowledge, APOE (located on chromosome 19) has a key 
role in coordinating the mobilization and redistribution of cholesterol, phospholipids, and 
fatty acids, and it is implicated in mechanisms such as neuronal development, brain 
plasticity, and repair functions (Mahley and Rall, 2000). In imaging genetics research 
experiments, several whole-brain studies focused on mapping this genetic risk factor 
(Filippini et al., 2009; Liu et al., 2015). Accordingly, in our experiments, we focus on the 
susceptibility SNP rs429358, which is determined using APOE ε2/ε3/ε4 status information 
(www.snpedia.com/index.php/APOE) from the ADNI clinical database for each participant. 
As shown in Figure 1, there are three subtypes according to the relationship between APOE 
ε2/ε3/ε4 and the two SNPs (i.e., rs429358 and rs7412). And the allelic variant on rs429358 
corresponds to the absence or presence of APOE ε4: (1) allele C at rs429358 indicates an ε4 
allele, and (2) allele T at rs429358 indicates a none- ε4 allele (i.e., ε2 or ε3).
In our experiments, rs429358 value was coded in an additive fashion as 0, 1 or 2, indicating 
the number of minor alleles (i.e., C alleles or APOE ε4 copies). If we considered APOE ε4 
as our target genetic risk of AD, the value was also coded as 0, 1 or 2, but indicating the 
number of APOE ε4 copies. Thus, the association study results on rs429358 should be 
consistent with the results on APOE ε4.
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Imaging phenotype data
The MRI, FDG-PET, and AV45-PET data used in this paper were also obtained from the 
ADNI database (adni.loni.usc.edu). We aligned the preprocessed multi-modality imaging 
data (VBM, FDG, AV45) to each participant’s same visit scan, and then created normalized 
gray matter density maps from MRI data in the standard Montreal Neurological Institute 
(MNI) space as 2×2×2 mm3 voxels, registered the FDG-PET and AV45-PET scans into the 
same space by SPM software package (Ashburner and Friston, 2007). 116 ROI level 
measurements of mean gray matter densities, FDG-PET glucose utilization, and AV45 
amyloid values were further extracted based on the MarsBaR AAL atlas (Tzourio-Mazoyer 
et al., 2002). After removal of cerebellum, the imaging measures on each modality (VBM, 
FDG or AV45) of 90 ROIs were used as QTs in our experiments. All the measures were pre-
adjusted for age, gender, and education.
Methods
Associations between Genotype and Phenotype
In this section, we systematically develop our computational models to explore the 
association between risk candidate SNPs and imaging phenotypes. Our proposed method 
mainly addresses the problem based on the general linear (least square) regression approach. 
Given the imaging phenotypes X = [x1, …, xn, …, xN]T ∊ RN×d as input and a pre-selected 
candidate SNP y= [y1, …, yn, …, yN]T ∊ RN as output in the regression model, where N is 
the number of participants (sample size) and d is the number of imaging QTs (feature 
dimensionality). The association model is designed to solve:
(1)
where R(w) is a regularization term and λ is the corresponding regularization parameter. 
The weight vector w measures the relative importance of the imaging QTs in predicting the 
SNP genotype. To encourage the ‘sparsity’ among features, in the Lasso method a l1-norm 
regularization is imposed on the coefficients as follows:
(2)
where λ is a regularization parameter that controls the sparsity in the solution. The non-zero 
elements of indicate that the corresponding input features are relevant to the regression 
outputs. This penalized regression method imposes l1-norm sparisty on the individual 
variables for feature selection (Kohannim et al., 2012; Tibshirani, 2011).
Following the existing work (Wang et al., 2012a), it’s worth noting that the above 
mathematical formulations are also used for association studies between genotypes and 
phenotypes. In this prior work, the goal of the learned regression model was not only on the 
genotype prediction accuracy, but also on identifying biologically meaningful SNP and 
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imaging markers and discovering the underlying complex biological mechanisms of the 
diseases, when the linear regression as the formulation of Eq (1) was applied to exploring 
the imaging genetic associations.
Diagnosis-guided Single-modality Phenotype Associations
A risk genetic factor may affect multiple imaging QTs that are not all disease specific. We 
aim to discover only those imaging QTs associated with both the genetic factor and disease 
status, in order to have a better understanding of the biological pathway specific to the 
disease. In this study, we consider the relationship between imaging phenotypes and the 
diagnosis information which are not fully used in conventional imaging genetics methods. 
More specifically, we will utilize the subjects’ diagnostic information, i.e., HC, SMC, 
EMCI, LMCI, or AD. If subjects are similar to each other in the original feature space, their 
respective response values (i.e., predicted genotype values) should be also similar. Figure 2 
illustrates an example of embedding the diagnosis information (i.e., clinical status) from 
original data to the mapped data space. To address this issue, we induce a new regularization 
term that can preserve the class level diagnosis information:
(3)
where S = [Sij] ∊ Rn×n denotes a similarity matrix that measures the diagnostic similarity 
between every pair of samples. L = D − S is the Laplacian matrix of S, where D is the 
diagonal matrix with element defined as . Then, the similarity matrix can be 
defined as:
(4)
The penalized term Eq (3) enforces that, after being mapped into the label space, the 
distance between the within-class data will be small. The similarity between subjects within 
the same class can be defined as 1 if connected or 0 otherwise, which avoids the necessity of 
choosing hyper-parameter compared to using heat kernel (Belkin and Niyogi, 2003). Eq (3) 
can be applied to an existing regression model (e.g., Eq (2)) so that the mapping of the data 
into the label space will not only be determined by the regression model but also be 
regularized by Eq (3). The goal of the Eq (3) term is to encourage subjects from the same 
class to be close to each other in the label space.
With these observations, we induce the diagnosis labels constraint into the single modality 
phenotypic solution and then formulate the diagnosis-guided single modality (DGSM) 
phenotype association model as follows:
(5)
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The strength of DGSM method is that it explicitly models the priori diagnosis information 
among subjects in the objective function that minimizes distance within each diagnostic 
class for selecting the disease-relevant QTs associated with the SNP. Especially, the DGSM 
model can generalize and handle the progressive disease with multi-diagnosis status, 
comparing to the binary diagnosis analysis methods that were adopted in (Batmanghelich et 
al., 2013; Vounou et al., 2012).
Concatenating-modality Phenotype Associations
A common practice in data fusion is the concatenation of all features from different 
modalities into a longer feature vector, which may provide essential complementary 
information for this association study. Given N training subjects or samples with M 
modalities of phenotypes, we denote  as the data 
matrix of the m-th modality, 
as the concatenating matrix of the M modalities and y= [y1, …, yn, …, yN]T ∊ RN be the 
corresponding response value (i.e. APOE SNP rs429358). Let wc = [w1, …, wm, …, wM]T ∊ 
RM·d be the linear discriminant function corresponding to the M modalities. Then the 
concatenating-modality phenotype association model that based on Lasso for sparsity 
solution can be formulated as follows:
(6)
Diagnosis-guided Concatenating-modality Phenotype Associations
Following the diagnosis-guided single modality phenotype associations, we also embed the 
diagnosis information into the concatenating-modalities to discover the phenotypic 
associations with an AD genetic risk factor. Thus, we induce the diagnosis label constraint 
based on Eq (6), and then formulate a diagnosis-guided concatenating-modality (DGCM) 
phenotype association model as follows:
(7)
where  denotes a similarity matrix that measures the similarity between 
every pair of samples on the concatenating M modalities across different subjects. Here, Lc 
= Dc − Sc represents a Laplacian matrix for the concatenating M modalities, where Dc is the 
diagonal matrix with element defined as . λ1 and λ2 denote control parameters 
of the regularization terms, respectively.
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Multi-modality Phenotype Associations
Intuitively, since the pathological changes from the same ROIs can be examined through 
structural and functional radiologic imaging, simultaneously performing ROI feature 
selections across multimodalities is very helpful to suppress noises in the individual 
modality features. We assume that there are N training subjects or samples, with each 
represented by M modalities of phenotypes. Denote 
as the data matrix of the m-th modality, and y= [y1, …, yn, …, yN]T ∊ RN be the 
corresponding response value (i.e. APOE SNP rs429358). Let wm ∊ Rd be the linear 
discriminant function corresponding to the m-th modality. Then the multi-modality 
phenotype association model can be formulated as follows:
(8)
where W = [w1,w2, …, wM] ∊ Rd×M is the weight matrix whose row wj is the vector of 
coefficients assigned to the j-th feature across different modalities, and 
is to penalize all coefficients in the same row of matrix W for joint feature selection. It is 
worth noting that the l2,1-norm regularization term is a “group-sparsity” regularizer, which 
forces only a small number of features to be selected from different modalities (Yuan and 
Lin, 2006). Figure 3 shows schematic illustration of diagnosis-guided multi-modality 
phenotype associations. The parameter λ is a regularization parameter that is used to 
balance the relative contributions of those two terms in Eq (8).
Diagnosis-guided Multi-modality Phenotype Associations
In this study, we propose to develop a novel diagnosis-guided multi-modality (DGMM) 
framework to discover the multi-modality phenotypic associations with an AD genetic risk 
factor, where the framework explicitly models the priori diagnosis information among 
subjects in the objective function for selecting the disease-relevant and ROI-consistent multi-
modality QTs associated with the SNP. Sample label relations and multi-modalities have 
recently been successfully investigated and applied to design more powerful models on AD 
classification and clinical scores regression (Jie et al., 2015; Yu et al., 2014; Zhu et al., 
2014a; Zhu et al., 2015; Zhu et al., 2013; Zhu et al., 2014b), which are inspired by using 
multi-task learning framework and taking into account the priori relationship between 
sample data and the corresponding labels in machine learning community (Belkin et al., 
2006). Thus, we induce the diagnosis label constraint into the multi-modality phenotypic 
solution, and then formulate a diagnosis-guided multi-modality (DGMM) phenotype 
association model as follows:
(9)
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where  denotes a similarity matrix that measures the similarity between 
every pair of samples on the m-th modality across different subjects. Here, Lm = Dm − Sm 
represents a combinational Laplacian matrix for the m-th modality, where Dm is the diagonal 
matrix with element defined as . λ1 and λ2 denote control parameters of the 
regularization terms, respectively. Their values can be determined via inner cross-validation 
on training data. In short, the above model is designed to find the better solution that is 
robust to noises or outliers via considering both multimodalities and the rich information 
inherent in the observations.
Optimization Algorithm
A similar model has been used in (Jie et al., 2015; Zhu et al., 2013) for multimodality 
disease classification. The objective function can be efficiently solved using the Nesterov’s 
accelerated proximal gradient optimization algorithm (Chen et al., 2009), via solving the 
optimization problem on the Eq (9). Algorithm 1 shows such an efficient solution.
Firstly, we separate the objective function into the smooth part Eq (10) and non-smooth part 
Eq (11) as following:
(10)
(11)
We define the approximation function Eq (12) as following, which is composited by the 
above smooth part and non-smooth one:
(12)
where  denotes the Frobenius norm, ∇f(Wi) denotes the gradient of f(W) on point W1 at 
the i-th iteration, and l is the step size. Finally, the update step of Nesterov’s APG is defined 
as:
(13)
where wj and vj denote the j-th row of the matrix W and V, respectively. NAGP performs a 
simple step of gradient descent to go from Wi to V, and then it slides a little bit further than
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(14)
Therefore, through Eq (12), this problem can be decomposed into d separate sub-problems. 
The key of APG algorithm is how to solve the update step efficiently. The analytical 
solutions of those sub-problems can be easily obtained:
(15)
Instead of performing gradient descent based on Wi, we compute the search point as (Beck 
and Teboulle, 2009):
(16)
where  and .
Algorithm 1
to minimize J in Equation (9)
Input: risk genetics (i.e. APOE) y= [y1, …, yn, …, yN]T ∊ RN,
  multi-modalities Xm = X1
m,…,Xn
m,…,XN
m T ∈ RN × d,
  subjects with diagnosis labels (i.e., HC, SMC, EMCI, LMCI or AD)
Output: Wi, J*
Initialization: l0 = 1, σ = 2, W0 = Z1 = 0, ρ0 = 1, I=1000
For i=1 to max_iteration I
1 Computed the search point Zi according to Eq (16)
2 l = li−1
3 while (f(Wi) + g(Wi)) > Ω(Wi, Zi), l = σl; Here Wi is computed by Eq (13)
4 Set li ← l
End
Calculate J*
Experimental Results
Experimental Settings
In our experiment, 5-fold cross-validation strategy was adopted to evaluate the effectiveness 
of our proposed method. As for parameters of regularization, we determined their values by 
nested 5-fold cross-validation on the training set. It was to fine tune the parameters (λ1 and 
λ2 in Eq(9)) in the range of {10−5, 3×10−5, 10−4, 3×10−4…, 3, 10}. In current studies, we 
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compared SM (denoted as single modality based method with Lasso (Tibshirani, 2011) to 
detect a sparse significant subset from imaging phenotypic features (i.e., ROI measures)), 
CM (denoted as concatenating modalities with Lasso to detect a sparse subset from imaging 
phenotypes), MM (denoted as multi-modality method to detect imaging phenotypes from a 
sparse subset of common ROIs), and DGSM, DGCM and DGMM (denoting DG as 
diagnosis-guided added methods corresponding to the standard SM, CM and MM, 
respectively).
Improved Association between Risk SNP and Multi-modal Phenotypic Imaging Markers
We compare our proposed diagnosis-guided based methods (including DGSM, DGCM and 
DGMM) with conventional methods (including SM, CM and MM), respectively. The 
performance on each dataset is assessed with root mean squared error (RMSE) and 
correlation coefficient (CC) between actual and predicted response values, which are widely 
used in measuring performances of regression and association analysis. The average results 
of RMSE and CC among the 5-fold training and testing data on MRI-VBM, FDG-PET and 
AV45 modalities are calculated respectively as shown in Table 2.
As shown in Table 2, DGSM yields the RMSE values of 0.8234, 0.8237, 0.8254 and CC 
values of 0.1565, 0.1624 and 0.1725 on three different modalities, respectively, which are 
better than those of SM. In addition, DGCM yields the RMSE values of 0.8236 and CC 
values of 0.1918, which are better than those of CM. Moreover, DGMM achieves the best 
RMSE values of 0.8214, 0.8229 and 0.8201 and the best CC values of 0.2484, 0.2345 and 
0.2545 on three different modalities, respectively, which are better than those of MM. These 
results indicate that the proposed DG based methods consistently outperform their non-DG 
based methods in both RMSE and CC performance measures. It’s worth noting that 
although the concatenation of all features can provide essential complementary information 
in ideal condition, CM-type models may be not enough for effective combination in this 
work as they brought more noises in widespread feature space. However, the multi-task 
strategy (i.e., l2,1-norm constrain) can enhance the robustness of ROI detection, which 
demonstrates that both diagnosis-guided priori knowledge and multi-modality information 
make it possible to improve the performances of regression and association from imaging 
phenotypes to genotype.
Identification of Consistent and Robust ROIs as Intermediate Phenotypes
Besides the improved performances, one major goal of this study is to identify some 
significant and robust phenotypes that are highly correlated to both risk SNP marker and 
disease status to capture imaging genetics associations in AD research. Figure 4 shows all 
comparisons of weight maps for the multi-modalities on 90 ROI associations with APOE 
SNP rs429358 respect to different methods. As expected, DGMM method can select sparse 
and significant ROIs associated with APOE rs429358. Although the SNP may affect 
different sets of ROIs while using different modalities as phenotype, the ROIs selected by 
our model tend to have all their modalities associated with the SNP and show great potential 
for further investigation. It is well known that the selected ROIs such as left hippocampus, 
right precuneus, left superior occipital gyrus and left calcarine gyrus are related to the 
structure atrophy, pathological amyloid depositions, and metabolic alteration in the brain 
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(Camus et al., 2012; Liu et al., 2015; Reiman et al., 1996; Wishart et al., 2006), showing 
effectiveness of the proposed method.
The top 10 selected MRI-VBM imaging features, as well as their average regression 
coefficients across five cross-validation trials, are visualized in Figure 5 by mapping them 
onto the human brain. The colors of the selected brain regions indicate the regression 
coefficients of the corresponding MRI-VBM markers. As expected, left hippocampus and 
left amygdala have been detected on top 10 ROIs associated with the risk genotype 
biomarker by the proposed DGMM method. It’s worth noting that these stable markers are 
in accordance with the previous studies. For example, the reduction of hippocampal gray 
matter has been correlated with APOE SNP rs429358 (Wishart et al., 2006).
The overall regression coefficients which are combinations of VBM, FDG and AV45 for the 
90 ROIs by DGMM test are plotted in Figure 6. The association weight map shows that the 
selected imaging markers by our proposed method have clear patterns that span across all 
the five cross-validation trials, and these identified phenotypic markers are from extremely 
stable ROIs such as left hippocampus, left superior occipital gyrus and left calcarine gyrus. 
In summary, the identified stable markers strongly agree with the existing findings. For 
example, the reductions of hippocampal gray matter and glucose metabolism for 
pathological changes have been shown to be associated with the best established genetic risk 
factor APOE polymorphism (Camus et al., 2012; Liu et al., 2015; Reiman et al., 1996; 
Wishart et al., 2006). Hence, these consistent ROIs detected by our proposed DGMM are 
closer to the underlying pathogenic location of the disease and the drug targeting for 
treatment in the future.
Discussion
In this paper, we have proposed a novel diagnosis-guided multi-modality (DGMM) 
framework to detect brain imaging phenotypes as intermediate QTs that are associated with 
both a certain risk genetic factor and disease status. The experimental results on 913 subjects 
from ADNI show that our DGMM model can substantially improve the performance of the 
associations. Specifically, for prediction and association measurements, our proposed 
method can achieve high average correlation coefficient values of 0.2484, 0.2345 and 0.2545 
on VBM, FDG, AV45 modalities, respectively. Besides the improved regression 
performances, our model can also identify some significant and robust phenotypic ROIs that 
reveal disease-specific imaging genetic associations on the chain from gene to brain to 
symptom.
Predictability from Phenotypes to Genotype
Similar to that used in our study for elucidating the associations between genotype and 
phenotype, the predicting formulations have been used in other imaging genetics association 
studies. In our work, the goal of the learned regression model is to select more biologically 
meaningful imaging phenotypes and discover the underlying complex biological 
mechanisms of the diseases. Here, we apply standard multivariate linear regression and R-
square measures to evaluate the imaging genetic associations. In statistics, R-square 
(explained variation / total variation) is a measure of how close the data are to the fitted 
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regression line. It is also known as the coefficient of determination, which provides a 
measure of how well observed outcomes are replicated by the model, based on the 
proportion of total variation of outcomes explained by the model (Draper, 2002). Table 3 
provides how successful the fit is in explaining the variation of the data (Putcha and Raton, 
2008), which indicate how much of the SNP genotypic variation can be explained by the 
different phenotypes (VBM, FDG and AV45, respectively). In this case, VBM measurement 
yields 3.5% (3.4% adjusted) explained capacity from left hippocampus (denoted HippL for 
short) to APOE, while both FDG and AV45 show weaker predictabilities. This is in 
accordance with the fact that in the pathology pathway of AD (Wishart et al., 2006). The 
proportion explained by top 10 consistent ROIs on each modality can achieve half adjusted 
R-square value of the predictabilities with all independent variables (90 ROIs). These results 
also demonstrate the promise of the proposed method in terms of its capability to identify 
the more significant brain ROIs associated with the top risk genotype.
Top Risk SNP vs Non-disease related SNP
The APOE polymorphism is the best established genetic risk factor for pathological changes 
that is also associated with anatomical brain changes (Liu et al., 2015). In our experiment, 
we test the performance on the top risk SNP APOE rs429358 in the DGMM framework, as 
reported in Table 2. We also selected a non-AD related SNP rs12410166 as the comparison 
to evaluate the performance of the proposed model. As shown in Table 4, all methods 
(including our DGMM framework) yielded very low average correlation coefficients 
measures, compared to that of top risk SNP APOE reported in Table 2. The model with 
irrelevant priori information embedding has leaded over-fitting on the badly noisy train data, 
meanwhile, has lost the power of generalization on test data. The originality of the work is to 
make full use of the risk genotype and corresponding disease samples to find the 
intermediate phenotype between an AD genetic marker and the disease status. Therefore, 
this set of contrast experiment has demonstrated that the pattern of consistent multimodal 
intermediate phenotypes we learned from the model only by using AD related SNP can 
capture the potential of interpreting the biological pathway from gene to brain to diagnosis.
Multi-locus Genetic Association Models vs Top Risk SNP Associations
In the existing studies, multi-locus genetic associations are used to discover reliable genetic 
influences with small effect size by adopted multivariate approaches such as statistical 
methods and machine learning techniques (Hibar et al., 2011; Shen et al., 2014). Here, we 
will review some multi-locus genetic marker detections in existing literatures which include 
diagnosis based methods (Batmanghelich et al., 2013; Vounou et al., 2012). In 
Batmanghelich et al’s Bayesian model, APOE ε4 and APOE ε3 were selected to be strongly 
correlated with AD under the highest posterior probability. And also, variants on APOC1, 
TOMM40 and PVRL were among high probability regions (hippocampus and temporal 
lobe) (Batmanghelich et al., 2013). In Vounou et al.’s two-step procedure identification, the 
experimental results showed PIK3R3/PIK3CG and PRKCA/PRKCB were important in 
driving selection of many pathways in the top 30 ranks. In addition, TOMM40, CR1 and 
APOE were in the top 10 ranking pathways, including ADCY2, ACTN1, ACACA and 
GNAI1, all of which were associated with AD related changes in hippocampal gene 
expression (Vounou et al., 2012). However, the focus of our work is not identifying several 
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multi-locus genetic patterns associated with phenotypes. However, it supplies a simple and 
efficient framework to identify intermediate imaging QTs that can bridge the gap between 
one top risk gene and a disease, comparing to the case control study.
Limitation
While aiming to develop an intermediate trait identification framework, the current study is 
limited by two factors. First, we associate only the top risk SNP (i.e., APOE rs429358), 
while AD is 50-70% heritable with complex genetic underpinnings, and an individual 
marker explains limited heritability of AD. Therefore, polygenic scores (Dudbridge, 2013; 
Sabuncu et al., 2012) that is considered as multi-locus genetic effect should be used in our 
DGMM model.
Second, for fair comparisons among SM-type models, we have reported the prediction 
accuracy of three imaging modalities separately. Actually, we haven’t designed a least 
squared error for joint prediction in the objective function. However, motivated by ensemble 
learning, we have averaged individual outputs learned by our DGMM for joint prediction 
denoted as DGMM (A-All). As shown in Table 5, the joint prediction results are superior to 
the separate ones on both training and test data. Furthermore, in order to investigate the 
relative contribution of each modality, we have extended weighted ensemble predictions 
denoted as DGMM (W-All). In our empirical study, we constrained the summation of 
individual weights was 1 and the optimal values were learned based on the training through 
a grid search using the range from 0 to 1 at a step of 0.1. The optimal weights have 
demonstrated that VBM and AV45 have larger contributions to the joint predictions. 
However, the contributed weight for each modality was not optimized from the objective 
function. Thus, it is an interesting future topic to apply our DGMM model to extend a one-
step joint association framework considering the relative contribution of each modality.
Third, as different imaging modalities can provide essential complementary information that 
can improve performances of accuracy, a lot of multi-modality based methods including 
concatenation and integrating among the feature level or other ensemble methods (Liu et al., 
2012) such as kernel combination (Jie et al., 2015; Zhang et al., 2011) and random forest 
(Gray et al., 2013) have been widely address the classification and prediction problem. 
However, our goal is to identify major ROIs whose multimodal measures can serve as 
intermediate traits, ignoring the diversity of the multi-modality phenotypes. We happen to 
induce existing multi-task learning aspect (Jie et al., 2015; Yuan and Lin, 2006; Zhang and 
Shen, 2012) for joint selecting the robust and consistent ROIs among different quantitative 
brain phenotypes for underlying the mechanisms of the disease. In order to balance the 
aspects of multi-modality phenotypic diversities and consistent ROIs selection in the 
association analysis above, we expect to use a more powerful model that can examine both 
individual (one ROI with certain modality phenotype) and shared features (the same ROIs 
among all modality phenotypes) of the different quantitative brain phenotypes to further 
improve our multimodal intermediate phenotypes identification. In the future work, we will 
address the above limitations for further improvement.
Hao et al. Page 14
Neuroinformatics. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusions
In summary, this study developed a diagnosis-guided multi-modality (DGMM) framework 
for identifying neuroimaging quantitative phenotypes which can server as intermediate traits 
between a certain risk genetic factor and disease status. This approach explicitly utilized the 
priori diagnosis information among subjects in the objective function for selecting the most 
relevant multi-modality QTs associated with top risk SNP (i.e., APOE rs429358) in one step. 
The empirical experiments on the ADNI database showed that our method improved 
performances under the metrics of both correlation coefficient and root mean squared error 
compared with other competing methods. Specifically, the main contribution of this work 
was to identify a compact set of robust and consistent ROIs across the multimodal 
phenotypes (i.e., MRI-VBM, FDG-PET and AV45) to have a mechanistic understanding of 
AD biology. This general DGMM framework can be extended and applied to identify 
potential intermediate traits for genetic studies of other disorders.
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Figure 1. 
Illustration of allelic variants of APOE ε2/ε3/ε4
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Figure 2. 
Schematic illustration of the diagnosis information (i.e., clinical status) embedded from 
original data to mapped data.
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Figure 3. 
Schematic illustration of multi-modality phenotype associations
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Figure 4. 
Weight maps for the multi-modalities on 90 ROI associations with APOE SNP rs429358 
respect to different methods.
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Figure 5. 
Visualization of the top 10 VBM ROIs selected by the proposed method. The color 
represents the regression coefficients of the corresponding VBM markers.
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Figure 6. 
Weight maps on the associations between diagnosis-guided consistent 90 ROI imaging 
markers and APOE rs429358 across five cross-validation trials by proposed DGMM 
methods.
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Table 1
Characteristics of the subjects
Subjects HC SMC EMCI LMCI AD
Number 211 82 273 187 160
Gender(M/F) 109/102 33/49 153/120 108/79 95/65
Age(mean±std) 76.14±6.53 72.45±5.67 71.48±7.12 73.86±8.44 75.18±7.88
Education (mean±std) 16.45±2.62 16.78±2.67 16.08±2.62 16.38±2.81 15.86±2.75
Note: HC=Healthy Control, SMC=Significant Memory Concern, ECMI=Early Mild Cognitive Impairment, LCMI=Late Mild Cognitive 
Impairment, AD=Alzheimer’s disease.
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Table 2
Comparison of regression performances on top risk SNP APOE rs429358 of the competing methods in terms 
of Root Mean Square Error (RMSE) and Correlation Coefficient (CC)
Method RMSE(mean±std) CC(mean±std)
train test train test
SM(VBM) 0.8628±0.0408 0.8723±0.0489 0.0658±0.0456 0.0184±0.0666
SM(FDG) 0.8817±0.1061 0.9062±0.1668 0.0253±0.0679 0.0316±0.0941
SM(AV45) 0.8940±0.0095 0.8963±0.0589 0.0075±0.0171 0.0264±0.0835
DGSM(VBM) 0.8231±0.0063 0.8234±0.0261 0.2145±0.0821 0.1565±0.0846
DGSM(FDG) 0.8238±0.0064 0.8237±0.0259 0.2206±0.0641 0.1624±0.0560
DGSM(AV45) 0.8203±0.0087 0.8254±0.0259 0.2535±0.0749 0.1725±0.0596
CM 0.9276±0.1485 0.9361±0.1560 0.0242±0.0556 0.0436±0.0727
DGCM 0.8235±0.0062 0.8236±0.0261 0.2383±0.0633 0.1918±0.1056
MM(VBM) 0.7644±0.0071 0.8752±0.0257 0.4370±0.0190 0.2107±0.0698
MM(FDG) 0.7679±0.0090 0.8836±0.0265 0.4238±0.0172 0.1695±0.0527
MM(AV45) 0.7606±0.0071 0.8730±0.0271 0.4518±0.0161 0.2286±0.0677
DGMM(VBM) 0.7886±0.0079 0.8214±0.0314 0.3688±0.0207 0.2484±0.0570
DGMM(FDG) 0.7901±0.0087 0.8229±0.0262 0.3605±0.0195 0.2345±0.0676
DGMM(AV45) 0.7877±0.0085 0.8201±0.0322 0.3805±0.0176 0.2545±0.0572
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Table 3
Predictability from Phenotypes to Genotype APOE rs429358 via R-square Statistical measures
R-square Adjusted R-square
Modality HippL Top10ROIs 90ROIs HippL Top10ROIs 90ROIs
VBM 0.035 0.093 0.189 0.034 0.083 0.1
FDG 0.005 0.051 0.174 0.004 0.04 0.083
AV45 0.01 0.09 0.203 0.009 0.08 0.115
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Table 4
Comparison of regression performances on random selected SNP rs12410166 of the competing methods in 
terms of Correlation Coefficient (CC)
Method CC(mean±std)
train test
SM(VBM) −0.0394±0.0670 0.0224±0.0977
SM(FDG) 0.0633±0.0311 −0.0221±0.0650
SM(AV45) 0.0542±0.0349 0.0092±0.0643
DGSM(VBM) 0.0617±0.0442 −0.0113±0.0521
DGSM(FDG) 0.0821±0.0213 −0.0344±0.0370
DGSM(AV45) 0.0797±0.0883 −0.0126±0.0945
CM 0.0100±0.0205 0.0032±0.0918
DGCM 0.0698±0.0295 −0.0289±0.0881
MM(VBM) 0.3470±0.0192 0.0372±0.0328
MM(FDG) 0.3594±0.0104 0.0521±0.0585
MM(AV45) 0.3479±0.0190 0.0352±0.0417
DGMM(VBM) 0.1845±0.1161 0.0320±0.0652
DGMM(FDG) 0.2324±0.0917 −0.0071±0.0589
DGMM(AV45) 0.1808±0.1190 0.0338±0.0551
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Table 5
performance comparisons of separate and joint association study by our proposed DGMM in terms of Root 
Mean Square Error (RMSE) and Correlation Coefficient (CC)
Method RMSE(mean±std) CC(mean±std)
train test train test
DGMM(VBM) 0.7886±0.0079 0.8214±0.0314 0.3688±0.0207 0.2484±0.0570
DGMM(FDG) 0.7901±0.0087 0.8229±0.0262 0.3605±0.0195 0.2345±0.0676
DGMM(AV45) 0.7877±0.0085 0.8201±0.0322 0.3805±0.0176 0.2545±0.0572
DGMM(A-ALL) 0.7841±0.0083 0.8164±0.0293 0.4309±0.0116 0.2895±0.0269
DGMM(W-All) 0.7838±0.0087 0.8160±0.0285 0.4393±0.0133 0.2938±0.0149
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